Les Tari
About Les Tari
Les Tari - Chief Scientific Officer
Les Tari serves as the Chief Scientific Officer. With a robust educational background and extensive experience in the field, Tari has become a prominent figure in the scientific community. His leadership roles in various companies and over 19 years of experience in early-stage drug discovery have equipped him with a wealth of knowledge and expertise.
Education and Expertise of Les Tari
Les Tari holds a Bachelor of Science in Chemistry and a Ph.D. in Chemistry and Structural Biology from the University of Manitoba. His academic credentials are further strengthened by his time as an Alberta Heritage Foundation Scholar for Medical Research at the University of Calgary, where he focused his research on antibiotic discovery. Tari's deep knowledge in chemistry and structural biology underpins his work in drug discovery.
Les Tari's Experience in Drug Discovery
Les Tari has accumulated over 19 years of experience in early-stage drug discovery. His professional journey spans both industry and academia, encompassing vital roles and significant contributions to the field. Tari has been involved in the design and development of the first industrial high-throughput structural genomics platform at Syrrx Inc., which was central to the company's success in early biological research.
Les Tari's Role at Trius Therapeutics and ActiveSight Inc.
From 2007 until its acquisition by Cubist Pharmaceuticals in 2013, Les Tari held positions of increasing responsibility at Trius Therapeutics. He was also a co-founder and Director of Structural Biology at ActiveSight Inc. from 2003 to 2007, leading all research efforts in inflammation and oncology. His leadership roles have consistently been at the forefront of advancing drug discovery efforts.
Les Tari's Publications and Patents
Les Tari is an author or inventor on over 50 publications and patents. His contributions to scientific literature and innovation testify to his role as a thought leader and innovator in the field of chemistry and structural biology. His research outputs provide valuable insights into the mechanisms of drug discovery and development.